...
首页> 外文期刊>Southern Med Review >Medicines information in medical journal advertising in Australia, Malaysia and the United States: A comparative cross-sectional study
【24h】

Medicines information in medical journal advertising in Australia, Malaysia and the United States: A comparative cross-sectional study

机译:澳大利亚,马来西亚和美国的医学期刊广告中的药物信息:比较横断面研究

获取原文

摘要

id="__p1" class="p p-first">Objective: The aim of this study was to compare the provision of medicines information in medical journal advertising in Australia, Malaysia and the United States. id="__p2">Methods: A consecutive sample of 85 unique advertisements from each country was selected from the advertisements published between January 2004 to December 2006 in three widely circulated medical journals and one prescribing reference manual. The availability of brand name and generic name, indication, contraindications, dosage, side-effects, warnings, interactions and precautions was compared between the three countries. id="__p3">Results: We examined 255 distinct advertisements for 136 pharmaceutical products. Journal advertising in Australia, Malaysia and the US usually provided brand names and generic names (range 96 -100%). Information on dosage was significantly less likely to be mentioned (32%) in the US than in Australia (92%) and Malaysia (48%) (P < 0.001). Warning information was significantly less likely to be provided in Australia (5%) than in the US (81%) and Malaysia (9%) (P < 0.001). Apart from information on brand name, generic name, warnings and dosage, other product information significantly less likely to be provided in journal advertising in Malaysia than in Australia and the US (P < 0.001). Similar trends in the provision of product information for the same medicines published in these countries were noted. Brand name and generic name were always provided in the three countries (100%). However, information on the negative effects of medicines was less frequently provided in Malaysia than in Australia and the US. id="__p4" class="p p-last">Conclusions: Journal advertising in Australia, Malaysia and the US failed to provide complete product information. Low quality of information provided in Malaysia indicates the need for effective regulation of provision of medicines information in journal advertising. Different standards of medicines information provided in these three countries suggest that pharmaceutical promotion needs to be better controlled at the international level.
机译:id =“ __ p1” class =“ p p-first”>目的:本研究的目的是比较澳大利亚,马来西亚和美国在医学期刊广告中提供的药物信息。 id =“ __ p2 “>方法:从2004年1月至2006年12月间在三种广为流传的医学期刊和一份处方参考手册中刊登的广告中,连续选取了来自每个国家的85个独特广告。比较了三个国家/地区的品牌名称和通用名称,适应症,禁忌症,剂量,副作用,警告,相互作用和预防措施的可用性。 id =“ __ p3”>结果:我们检查了136种药品的255个不同的广告。澳大利亚,马来西亚和美国的期刊广告通常提供品牌名称和通用名称(范围为96 -100%)。与澳大利亚(92%)和马来西亚(48%)相比,美国很少提及剂量信息(32%)(P <0.001)。与美国(81%)和马来西亚(9%)相比,澳大利亚(5%)提供警告信息的可能性大大降低(P <0.001)。除了关于品牌名称,通用名称,警告和剂量的信息外,与澳大利亚和美国相比,马来西亚的期刊广告提供的其他产品信息的可能性也大大降低(P <0.001)。注意到在这些国家发布的相同药品的产品信息提供方面的类似趋势。在三个国家/地区始终提供品牌名称和通用名称(100%)。但是,与澳大利亚和美国相比,在马来西亚提供药物负面影响的信息较少。 id =“ __ p4” class =“ p p-last”>结论:在澳大利亚,马来西亚和美国的期刊广告均未通过提供完整的产品信息。马来西亚提供的信息质量低下,表明需要有效监管期刊广告中药品信息的提供。这三个国家提供的药物信息标准不同,表明需要在国际一级更好地控制药物推广。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号